119 related articles for article (PubMed ID: 37956625)
1. Multi-cohort validation study of a four-gene signature for risk stratification and treatment response prediction in hepatocellular carcinoma.
Liu C; Xiao Z; Wu S; Yang Z; Ji G; Duan J; Zhou T; Cao J; Liu X; Xu F
Comput Biol Med; 2023 Dec; 167():107694. PubMed ID: 37956625
[TBL] [Abstract][Full Text] [Related]
2. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
[TBL] [Abstract][Full Text] [Related]
3. Gene signature predictive of hepatocellular carcinoma patient response to transarterial chemoembolization.
Fako V; Martin SP; Pomyen Y; Budhu A; Chaisaingmongkol J; Franck S; Lee JM; Ng IO; Cheung TT; Wei X; Liu N; Ji J; Zhao L; Liu Z; Jia HL; Tang ZY; Qin LX; Kloeckner R; Marquardt J; Greten T; Wang XW
Int J Biol Sci; 2019; 15(12):2654-2663. PubMed ID: 31754337
[TBL] [Abstract][Full Text] [Related]
4. A novel prognostic signature based on immunogenic cell death score predicts outcomes and response to transcatheter arterial chemoembolization and immunotherapy in hepatocellular carcinoma.
Zhang Y; Yang J; Xie S; Chen H; Zhong J; Lin X; Yu Z; Xia J
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11411-11429. PubMed ID: 37382674
[TBL] [Abstract][Full Text] [Related]
5. A Novel Ferroptosis-Related Signature for Prediction of Prognosis, Immune Profiles and Drug Sensitivity in Hepatocellular Carcinoma Patients.
Zhao C; Zhang Z; Tao J
Curr Oncol; 2022 Sep; 29(10):6992-7011. PubMed ID: 36290827
[TBL] [Abstract][Full Text] [Related]
6. Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma.
Xiong X; Song Q; Jing M; Yan W
Genet Res (Camb); 2023; 2023():6879022. PubMed ID: 37313428
[TBL] [Abstract][Full Text] [Related]
7. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
Wang Y; Song F; Zhang X; Yang C
Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359
[TBL] [Abstract][Full Text] [Related]
9. Basement membrane-related regulators for prediction of prognoses and responses to diverse therapies in hepatocellular carcinoma.
Ding R; Zhao C; Jing Y; Chen R; Meng Q
BMC Med Genomics; 2023 Apr; 16(1):81. PubMed ID: 37081465
[TBL] [Abstract][Full Text] [Related]
10. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
[TBL] [Abstract][Full Text] [Related]
11. MiR-125b Loss Activated HIF1α/pAKT Loop, Leading to Transarterial Chemoembolization Resistance in Hepatocellular Carcinoma.
Wei X; Zhao L; Ren R; Ji F; Xue S; Zhang J; Liu Z; Ma Z; Wang XW; Wong L; Liu N; Shi J; Guo X; Roessler S; Zheng X; Ji J
Hepatology; 2021 Apr; 73(4):1381-1398. PubMed ID: 32609900
[TBL] [Abstract][Full Text] [Related]
12. A novel stemness-hypoxia-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma.
Zhang G; Zhang K; Zhao Y; Yang Q; Lv X
BMC Cancer; 2022 Oct; 22(1):1103. PubMed ID: 36307751
[TBL] [Abstract][Full Text] [Related]
13. Integrated analysis revealing a novel stemness-metabolism-related gene signature for predicting prognosis and immunotherapy response in hepatocellular carcinoma.
Wang Y; Wan X; Du S
Front Immunol; 2023; 14():1100100. PubMed ID: 37622118
[TBL] [Abstract][Full Text] [Related]
14. An immune-related signature for optimizing prognosis prediction and treatment decision of hepatocellular carcinoma.
Yao N; Jiang W; Wang Y; Song Q; Cao X; Zheng W; Zhang J
Eur J Med Res; 2023 Mar; 28(1):123. PubMed ID: 36918943
[TBL] [Abstract][Full Text] [Related]
15. Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma.
He Q; Yang J; Jin Y
Front Immunol; 2022; 13():869993. PubMed ID: 35493518
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
17. The m
Ma E; Li J; Shen C; Gu Y; Zhang X; Li L; Zhao J; Wang Z
Front Immunol; 2023; 14():1227593. PubMed ID: 37691948
[TBL] [Abstract][Full Text] [Related]
18. Construction and validation of a novel lysosomal signature for hepatocellular carcinoma prognosis, diagnosis, and therapeutic decision-making.
Chen J; Gao G; He Y; Zhang Y; Wu H; Dai P; Zheng Q; Huang H; Weng J; Zheng Y; Huang Y
Sci Rep; 2023 Dec; 13(1):22624. PubMed ID: 38114725
[TBL] [Abstract][Full Text] [Related]
19. Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma.
Niu XK; He XF
World J Gastroenterol; 2021 Jan; 27(2):189-207. PubMed ID: 33510559
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma.
Liang L; Li C; Wang MD; Wang H; Zhou YH; Zeng YY; Zhang WG; Chen TH; Wang NY; Li J; Zhang YM; Wang Y; Gu WM; Xing H; Diao YK; Lau WY; Zhang CW; Pawlik TM; Shen F; Huang DS; Yang T
J Hematol Oncol; 2021 Oct; 14(1):165. PubMed ID: 34641921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
